9 completed. 9 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 9 | Completed 9 |
Follow Complicated Urinary Tract Infection: new trials by email Literature Review of Complicated Urinary Tract Infection trials Research Report on Complicated Urinary Tract Infection
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| P3 Study to Assess Efficacy and Safety of Cefepime/Nacubactam and Aztreonam/Nacubactam Versus Best Available Therapy for Adults With Infection Due to Carbapenem Resistant Enterobacterales co-administration of cefepime and nacubactam, co-administration of aztreonam and nacubactam, BAT - Complicated Urinary Tract Infection, Acute Pyelonephritis | Phase 3 | Completed | Meiji Seika Pharma Co., Ltd. | 126 | 2023-09-22 | 2026-04-13 |
| Efficacy and Safety of Cefepime/Nacubactam or Aztreonam/Nacubactam Compared to Imipenem/Cilastatin in Subjects With Complicated Urinary Tract Infections or Acute Uncomplicated Pyelonephritis co-administration of cefepime and nacubactam, co-administration of aztreonam and nacubactam, imipenem/cilastatin - Complicated Urinary Tract Infection, Acute Pyelonephritis | Phase 3 | Completed | Meiji Seika Pharma Co., Ltd. | 614 | 2023-05-23 | 2025-12-24 |
| Study of Cefepime-zidebactam (FEP-ZID) in Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP) Cefepime-zidebactam (FEP-ZID), Meropenem - Complicated Urinary Tract Infection, Acute Pyelonephritis | Phase 3 | Completed | Wockhardt | 530 | 2022-08-28 | 2026-05-22 |
| Study to Assess the Efficacy, Safety and Pharmacokinetics of Orally Administered Tebipenem Pivoxil Hydrobromide (SPR994) Compared to Intravenous Ertapenem in Participants With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP) TBPM-PI-HBr, Ertapenem, Dummy Infusion - Complicated Urinary Tract Infection, Acute Pyelonephritis | Phase 3 | Completed | Spero Therapeutics | 1372 | 2019-06-03 | 2022-07-25 |
| Efficacy and Safety of Imipenem+Cilastatin/Relebactam (MK-7655A) in Japanese Participants With Complicated Intra-abdominal Infection or Complicated Urinary Tract Infection (MK-7655A-017) Imipenem+Cilastatin/Relebactam - Complicated Intra-abdominal Infection, Complicated Urinary Tract Infection | Phase 3 | Completed | Merck Sharp & Dohme LLC | 83 | 2017-10-04 | 2021-02-12 |
| Study of Ceftolozane/Tazobactam (MK-7625A) in Japanese Participants With Uncomplicated Pyelonephritis and Complicated Urinary Tract Infection (MK-7625A-014) MK-7625A 1.5 g (ceftolozane 1 g/tazobactam 0.5 g) - Urinary Tract Infection (UTI), Complicated Urinary Tract Infection | Phase 3 | Completed | Merck Sharp & Dohme LLC | 115 | 2016-04-14 | 2019-02-05 |
| A Study of Plazomicin Compared With Meropenem for the Treatment of Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis (AP) plazomicin, meropenem, levofloxacin (oral) - Complicated Urinary Tract Infection, Acute Pyelonephritis | Phase 3 | Completed | Achaogen, Inc. | 609 | 2016-01-11 | 2018-08-23 |
| Ceftazidime-Avibactam for the Treatment of Infections Due to Ceftazidime Resistant Pathogens Ceftazidime - Avibactam ( CAZ-AVI), Best Available Therapy, Metronidazole - Complicated Urinary Tract Infection, Complicated Intra-abdominal Infection | Phase 3 | Completed | Pfizer | 345 | 2013-01-01 | 2017-09-29 |
| Study Comparing the Safety and Efficacy of Intravenous CXA-201 and Intravenous Levofloxacin in Complicated Urinary Tract Infection, Including Pyelonephritis CXA-201, Levofloxacin - Complicated Urinary Tract Infection, Pyelonephritis | Phase 3 | Completed | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 558 | 2011-06-20 | 2018-10-25 |
Pyelonephritis (2) · Bacterial Infections (1) · Urinary Tract Infections (1)
Female Urogenital Diseases (2) · Female Urogenital Diseases and Pregnancy Complications (2) · Infections (2) · Kidney Diseases (2) · Male Urogenital Diseases (2) · Nephritis (2) · Nephritis, Interstitial (2) · Pyelitis (2) · Urogenital Diseases (2) · Urologic Diseases (2) · Bacterial Infections and Mycoses (1)
Levofloxacin (2) · Meropenem (2) · nacubactam (2) · Cilastatin, Imipenem Drug Combination (1) · Ertapenem (1) · Metronidazole (1) · Tazobactam (1) · avibactam, ceftazidime drug combination (1) · cefepime-zidebactam (1) · ceftolozane (1) · imipenem, cilastatin and relebactam (1) · plazomicin (1) · tebipenem (1)
Meiji Seika Pharma Co., Ltd. (2) · Merck Sharp & Dohme LLC (2) · Achaogen, Inc. (1) · Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (1) · Pfizer (1) · Spero Therapeutics (1) · Wockhardt (1)
Slovakia (5) · Bulgaria (4) · Czechia (4) · Estonia (4) · Georgia (4) · Latvia (4) · United States (4) · China (3) · Israel (3) · Japan (3) · Mexico (3) · Poland (3) · Romania (3) · Russia (3) · South Africa (3)
David Melnick, MD (1) · Lynn E Connolly, MD, PhD (1) · Obiamiwe Umeh, M.D., MSc. (1) · Paul Newell, MBBS, MRCP (1)
PMID 25931244, PMID 26994090, PMID 27872067, PMID 27887579, PMID 27999024, PMID 28446129, PMID 28464828, PMID 29912399, PMID 30061279, PMID 30221827, PMID 30786187, PMID 30910899, PMID 32602065, PMID 33191112, PMID 35388666, PMID 37700689, PMID 42134354
2015 (1), 2018 (1)